日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級(jí)生物類似抗體
  4. LAG3 (Relatlimab Biosimilar) Recombinant Monoclonal Antibody

LAG3 (Relatlimab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號(hào)：
    CSB-RA012719MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    LAG3 (Relatlimab Biosimilar Antibody) 重組單克隆抗體是一種針對(duì)淋巴細(xì)胞活化基因3（LAG3）的重組單克隆抗體其，其別名為CD223抗體、CD223抗原抗體、FDC蛋白抗體、LAG-3抗體、Lag3抗體、LAG3_HUMAN抗體、淋巴細(xì)胞活化3抗體、淋巴細(xì)胞活化基因3抗體、淋巴細(xì)胞活化基因3蛋白抗體、Protein FDC抗體。該抗體以重組人LAG3蛋白制備而成，具有高度的種屬反應(yīng)性，主要針對(duì)人類LAG3蛋白發(fā)揮作用。 Relatlimab作為針對(duì)LAG3抗體的類似物，在腫瘤免疫治療中具有重要地位。LAG3作為關(guān)鍵的免疫檢查點(diǎn)分子，在腫瘤免疫逃逸中扮演重要角色。Relatlimab通過特異性結(jié)合LAG3，阻斷其與配體的相互作用，解除對(duì)T細(xì)胞的抑制，從而增強(qiáng)抗腫瘤免疫應(yīng)答。目前，Relatlimab的臨床應(yīng)用主要集中在多種實(shí)體瘤及血液系統(tǒng)惡性腫瘤的治療，尤其在黑色素瘤、非小細(xì)胞肺癌等適應(yīng)癥中展現(xiàn)出良好的療效潛力，常與PD-1/PD-L1抑制劑聯(lián)合使用以提高免疫治療效果，減少耐藥性的發(fā)生。 在該抗體為生命科學(xué)研究提供了有力工具。研究人員可利用其特異性識(shí)別和結(jié)合LAG3的特性，在細(xì)胞水平和動(dòng)物模型中深入探究LAG3的生物學(xué)功能，包括其在免疫調(diào)節(jié)、腫瘤微環(huán)境重塑、自身免疫性疾病發(fā)生發(fā)展中的作用機(jī)制。此外，通過實(shí)驗(yàn)，該抗體可用于檢測(cè)LAG3在不同組織和細(xì)胞中的表達(dá)水平及定位，為疾病診斷標(biāo)志物的篩選和治療靶點(diǎn)的驗(yàn)證提供實(shí)驗(yàn)依據(jù)，推動(dòng)相關(guān)領(lǐng)域的基礎(chǔ)研究和轉(zhuǎn)化醫(yī)學(xué)發(fā)展。
  • Uniprot No.：
  • 基因名：
  • 別名：
    CD223 antibody; CD223 antigen antibody; FDC protein antibody; LAG-3 antibody; Lag3 antibody; LAG3_HUMAN antibody; Lymphocyte activating 3 antibody; Lymphocyte activation gene 3 antibody; Lymphocyte activation gene 3 protein antibody; Protein FDC antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human LAG3 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲(chǔ)存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    In stock
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as FGL1. FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function. Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1. Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells. Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function. Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation. Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear.; May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.
  • 基因功能參考文獻(xiàn)：
    1. Results demonstrated that the expression of LAG3 in colorectal carcinoma tissue was significantly increased compared with the paracancerous tissue. It was mainly expressed at the edge of tumor tissues suggesting that LAG3 was expressed on tumorinfiltrating lymph node cells but not in colorectal cancer cells. PMID: 30272332
    2. These results together suggested that LAG-3 is a marker of CD4(+) T cells with regulatory function; at the same time, LAG-3 might have limited the full suppressive potential of Treg cells. PMID: 29671649
    3. Among the 89 patients, CD274, LAG3, and IDO1 expressions in TIICs were observed in 68.6% (61 cases), 13.5% (12), and 28.1% (25) of patients, respectively. CD274, CTLA4, and IDO1 were expressed in tumor cells of 24.7% (22 cases), 4.5% (4), and 72.0% (64) of patients, respectively. PMID: 29520442
    4. LAG-3+ iTILs are enriched in estrogen receptor-negative breast cancers and represent an independent favorable prognostic factor. In addition, a high proportion of PD-1/PD-L1+ tumors are co-infiltrated with LAG-3+ TILs. PMID: 29045526
    5. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors. PMID: 27835902
    6. Data suggest that blocking LAG3-MHC class II interactions is a potential therapeutic target in chronic lymphocytic leukemia. PMID: 28154084
    7. LAG-3 expression was correlated with expression of PD-1 on TILs and expression of PD-L1 on tumor cells. Higher expression of LAG-3 on TILs was significantly correlated with higher expression of PD-1 on TILs and higher expression of PD-L1 on tumor cells. PMID: 28132868
    8. the upregulation of others syncytial molecules, including LAG3, CTLA4, CD28 and CD3, assisting the formation of syncytia with APC cells. PMID: 27108398
    9. LAG3-expressing CD4(+)CD25(-) T cells represent another regulatory immune cell type with potential to interfere with anti-tumor immunity. PMID: 28935468
    10. Overexpression of lymphocyte activation gene-3 inhibits regulatory T cell responses in osteoarthritis PMID: 28800255
    11. Egr2-driven cell surface proteins LAG-3 and 4-1BB can identify dysfunctional tumor antigen-specific CD8(+) TIL. PMID: 28115575
    12. our data indicate that the evaluation of stromal TILs remains the most reliable immune prognostic marker in TNBC, and support the clinical evaluation of anti-PD-1/PD-L1 and anti-LAG-3 in a subset of patients with TNBC who have concurrent expression of both checkpoint receptors. PMID: 27912781
    13. this review provides the translational rationale for targeting LAG3, as well as historical and current state of clinical trials utilizing LAG3 cancer immunomodulators PMID: 28258692
    14. this study shows that LAG3 expressed on myeloid leukaemia cells possess the capacity to facilitate functional exhaustion in T helper cells PMID: 27565576
    15. epigenetic modification on LAG-3 increased LAG-3(+) T cells and its immune regulatory roles in chronic osteomyelitis progression PMID: 28028751
    16. Immune checkpoint proteins are co-inhibitory factors that can diminish the antigen-specific immune responses by attenuating the regulatory role of cytotoxic T-lymphocyte-associated protein 4, programmed cell death-1, lymphocyte-activation gene 3, and T-cell immunoglobulin mucin-3. PMID: 28349816
    17. LAG3 binds alpha-synuclein preformed fibrils (PFF) with high affinity (dissociation constant = 77 nanomolar), whereas the alpha-syn monomer exhibited minimal binding. alpha-Syn-biotin PFF binding to LAG3 initiated alpha-syn PFF endocytosis, transmission, and toxicity. PMID: 27708076
    18. An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy. PMID: 26013006
    19. LAG-3 is highly expressed in peripheral blood CD8+ T cells in chronic HBV-infected patients. PMID: 27053622
    20. iNKT cytokine production is profoundly altered by both HIV infection and treatment, and LAG-3, but not PD-1, expression is associated with a reduction in iNKT IFNgamma production. PMID: 25810006
    21. NFKB1, CD27, LAG3 and IKZF3 are new susceptibility genes for psoriasis. PMID: 25006012
    22. The elevated expression of LAG-3 at the genital tract suggests it may regulate T-cell activation, and identify cells susceptible to HIV infection. The enrichment of LAG-3 on double negative T cells suggests LAG-3 may contribute to the immunoregulatory activity of these cells. PMID: 25154740
    23. the LAG-3/MHC class II pathway may synergize with PD-1/PD ligand to enhance T cell-mediated immune responses. PMID: 25780040
    24. LAG-3 trafficking from lysosomal compartments to the cell surface is dependent on the cytoplasmic domain through protein kinase C signaling in activated T cells. PMID: 25108024
    25. These results suggest that LAG-3-mediated activation of plasmacytoid dendritic cells takes place in vivo at tumor sites, and it is in part responsible for directing an immune-suppressive environment. PMID: 24441096
    26. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. PMID: 23261718
    27. our data suggest that the LAG-3-MHC II interaction could be viewed as a bidirectional immune escape pathway in melanoma PMID: 21441454
    28. Multiple myeloma was associated with 2 SNPs in intron regions of LAG3 within 20 k base pairs 5' upstream of the candidate CD4 gene. The variant in LAG3 gene itself may play a role in susceptibility of MM. PMID: 20568250
    29. Analysis identified a gene-set (LAG3, LPL, ZAP70) whose overexpression is assigned to unmutated immunoglobulin variable heavy chain region with 90% specificity. PMID: 20228263
    30. LAG-3 defines an active CD4(+)CD25(high)Foxp3(+) regulatory T cell subset whose frequency is enhanced in the PBMCs of patients with cancer PMID: 20421648
    31. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. PMID: 20385810
    32. MHC class II-mediated signals induced by the natural ligand, LAG-3, lead to complete maturation of monocyte-derived dendritic cells, which acquire the capacity to trigger naive T cells and drive polarized Th1 responses. PMID: 11937541
    33. LAG-3 induces rapid protein phosphorylation of phospholipase Cgamma2 and p72syk as well as activation of phosphatidyl inositol 3-kinase/Akt, p42/44 extracellular signal-regulated protein kinase, and p38 mitogen-activated protein kinase pathways. PMID: 12775570
    34. LAG3 may mediate sphingolipid metabolism PMID: 12825348
    35. LAG-3 activates antigen-presenting cells through MHC class II signalling, leading to increased antigen-specific T-cell responses in vivo. PMID: 14644131
    36. regulatory T cells and LAG-3 have pivotal roles in the suppression of EBV-specific cell-mediated immunity in Hodgkin lymphoma PMID: 16757686
    37. The result, including a total of 2640 MS patients and 2194 controls shows no significant association with CD4 and LAG3 and MS. We conclude that these genes are of minor importance in regard of genetic predisposition to the MS. PMID: 17020785
    38. Soluble human recombinant fusion protein (hLAG-3Ig) used in vitro as a single maturation agent induces phenotypic maturation of monocyte-derived dendritic cells and promotes the production of chemokines and TNF-alpha inflammatory cytokine. PMID: 18322184

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    [Lymphocyte activation gene 3 protein]: Cell membrane; Single-pass type I membrane protein.; [Secreted lymphocyte activation gene 3 protein]: Secreted.
  • 組織特異性：
    Primarily expressed in activated T-cells and a subset of natural killer (NK) cells.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 6476

    OMIM: 153337

    KEGG: hsa:3902

    STRING: 9606.ENSP00000203629

    UniGene: Hs.409523



×
生命科學(xué)計(jì)算平臺(tái)